» Articles » PMID: 7537444

Tacrolimus: a Potential New Treatment for Autoimmune Chronic Active Hepatitis: Results of an Open-label Preliminary Trial

Overview
Specialty Gastroenterology
Date 1995 May 1
PMID 7537444
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Autoimmune chronic active hepatitis (CAH-A) is a chronic liver disease of unknown etiology that is believed to have an autoimmune pathogenesis. The disease is slowly progressive until hepatic failure and portal hypertension develop and either death or liver transplantation occur. Currently, the only widely recognized therapy is the administration of glucocorticoids, which have both anti-inflammatory and immunosuppressive actions. Many patients cannot tolerate such therapy because of the psychiatric, osteoporotic, and weight-enhancing actions of steroids. Tacrolimus (FK 506) is a new macrolide antibiotic that has an immunosuppressive activity that is estimated to be 10-200 times greater than that of cyclosporine. Because of its greater immunosuppressive activity, we have used it in the treatment of 21 patients with autoimmune chronic active hepatitis. Before each subject was treated, a liver biopsy and a panel of hematological, serological, and biochemical parameters were assessed. The Tacrolimus was administered orally at 12-h intervals, and the dose was controlled by monitoring plasma FK trough levels. After 3 months of therapy at an oral dose of 3 mg twice a day, having achieved a median blood level of 0.5 ng/ml, the serum ALT level was reduced by 80%, and the AST level was reduced by 70%. Modest change in the white blood cell count and platelet count were noted. The median BUN level increased from a level of 12 to 18 mg/dl, and the serum creatinine increased from 0.9 to 1.3 mg/dl. These preliminary data demonstrate that: 1) Tacrolimus can be used to successfully treat CAH-A; 2) the response of CAH-A to Tacrolimus treatment is rapid and sustained; and 3) a minor increase in the serum BUN and creatinine levels occurs as a consequence of Tacrolimus treatment. It is anticipated that with continued treatment for periods of 1-2 yr, the natural history of CAH-A will be changed such that hepatic failure and the requirement for liver transplantation may be averted.

Citing Articles

Autoimmune hepatitis: Towards a personalized treatment.

Costaguta A, Costaguta G, Alvarez F World J Hepatol. 2024; 16(11):1225-1242.

PMID: 39606175 PMC: 11586748. DOI: 10.4254/wjh.v16.i11.1225.


B and T cells: (Still) the dominant orchestrators in autoimmune hepatitis.

Longhi M, Zhang L, Mieli-Vergani G, Vergani D Autoimmun Rev. 2024; 23(7-8):103591.

PMID: 39117005 PMC: 11409799. DOI: 10.1016/j.autrev.2024.103591.


Tacrolimus versus mycophenolate for AutoImmune hepatitis patients with incompLete response On first-line therapy (TAILOR study): a study protocol for a phase III, open-label, multicentre, randomised controlled trial.

Stoelinga A, Tushuizen M, van den Hout W, Girondo M, de Vries E, Levens A Trials. 2024; 25(1):61.

PMID: 38233878 PMC: 10792789. DOI: 10.1186/s13063-023-07832-w.


Liver Disease and Sickle Cell Disease: Auto-Immune Hepatitis more than a Coincidence; A Systematic Review of the Literature.

Lynch K, Mega A, Daves M, Sadiq A, Fogarty H, Piccin A Mediterr J Hematol Infect Dis. 2023; 15(1):e2023060.

PMID: 38028400 PMC: 10631714. DOI: 10.4084/MJHID.2023.060.


Animal Models for Autoimmune Hepatitis: Are Current Models Good Enough?.

Christen U, Hintermann E Front Immunol. 2022; 13:898615.

PMID: 35903109 PMC: 9315390. DOI: 10.3389/fimmu.2022.898615.


References
1.
De Groote J, Fevery J, Lepoutre L . Long-term follow-up of chronic active hepatitis of moderate severity. Gut. 1978; 19(6):510-3. PMC: 1412017. DOI: 10.1136/gut.19.6.510. View

2.
Vento S, Eddleston A . Immunological aspects of chronic active hepatitis. Clin Exp Immunol. 1987; 68(2):225-32. PMC: 1542717. View

3.
Mieles L, Fung J, Yokoyama I, McCauley J, Singh N, Todo S . Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report. Transplant Proc. 1991; 23(6):3016-8. PMC: 2974314. View

4.
. Effect of prednisone on the survival of patients with cirrhosis of the liver. A report from the Copenhagen Study Group for Liver Diseases. Lancet. 1969; 1(7586):119-21. View

5.
Keating J, OBrien C, Stellon A, Portmann B, Johnson R, Johnson P . Influence of aetiology, clinical and histological features on survival in chronic active hepatitis: an analysis of 204 patients. Q J Med. 1987; 62(237):59-66. View